Results 51 to 60 of about 20,104,039 (259)

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature [PDF]

open access: yes, 2006
An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established.
Lakatos, Péter László   +4 more
core   +1 more source

Chronic hepatitis C: future treatment

open access: yesClinical Pharmacology: Advances and Applications, 2014
Astrid Wendt, Xavier Adhoute, Paul Castellani, Valerie Oules, Christelle Ansaldi, Souad Benali, Marc BourlièreDepartment of Hepato-Gastroenterology, Hôpital Saint-Joseph, Marseille, FranceAbstract: The launch of first-generation protease ...
Wendt A   +6 more
doaj  

GB Virus C Infection: Clinical Significance

open access: yesCanadian Journal of Gastroenterology, 1999
GB virus C (GBV-C) RNA positivity rates were examined in serum specimens from 231 patients with liver disease (23 patients with hepatitis B, 175 patients with hepatitis C, five patients with hepatitis B virus plus hepatitis C virus coinfection, and 28 ...
Xiang Wei Meng   +8 more
doaj   +1 more source

METABOLIC AND CARDIOVASCULAR COMORBIDITIES IN BULGARIAN PATIENTS WITH CHRONIC VIRAL B AND C HEPATITIS [PDF]

open access: yesJournal of IMAB
Recent epidemiologic data on chronic viral B and C hepatitis in Bulgaria are limited.The evolution of these infections depends on liver complications and the presence of nonliver comorbidities.
Radoslava Tsrancheva   +10 more
doaj   +1 more source

Identification of (20R)‐protopanaxadiol from Panax ginseng as a novel anti‐SARS‐CoV‐2 compound

open access: yesFEBS Open Bio, EarlyView.
We established a noninfectious BAC‐based SARS‐CoV‐2 replicon that enables antiviral screening under BSL‐2 conditions. Using this platform, we screened 373 food‐derived compounds and identified (20R)‐protopanaxadiol from Panax ginseng as a novel inhibitor of SARS‐CoV‐2 RNA replication, highlighting the value of safe replicon systems for antiviral ...
Midori Takeda   +4 more
wiley   +1 more source

Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin [PDF]

open access: yesVojnosanitetski Pregled, 2005
Background. Hepatitis C virus (HCV) infection is the most frequent cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma in the world. Acute hepatitis C is the most commonly asymptomatic liver disease with the development of chronic HCV ...
Delić Dragan   +4 more
doaj   +1 more source

Physicians Infrequently Adhere to Hepatitis Vaccination Guidelines for Chronic Liver Disease [PDF]

open access: yes, 2013
Background and Goals:Hepatitis A (HAV) and hepatitis B (HBV) vaccination in patients with chronic liver disease is an accepted standard of care. We determined HAV and HBV vaccination rates in a tertiary care referral hepatology clinic and the impact of ...
Dhiraj Yadav   +15 more
core   +2 more sources

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

open access: yesAging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Dendritic cell function in the setting of chronic hepatitis c infection and changes during antiviral treatment [PDF]

open access: yes, 2009
The role of the innate immune system and in particular of dendritic cells, in the establishment of chronic hepatitis C has been studied quite extensively over the last few years but controversy remains as to whether a potential virus-induced defect in
Pachiadakis, I.
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy